Scribe Therapeutics Secures 129 Million Dollar IPO to Scale Epigenetic Cardiovascular Therapies
Summary
CRISPR-based Scribe Therapeutics has gone public to advance genetic medicines that repress gene expression without permanent DNA alterations. The initial focus targets cardiometabolic diseases like ASCVD, signaling a shift for genetic medicine from rare diseases to massive patient populations.
The company works in Cardiovascular and Therapeutics, and this round at IPO is new money into that part of the market. Compare it with other recent rounds to see whether prices here are rising or holding steady. Note: relevant to women's health, but not only about women's health.
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.